Snapshot from Sep 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

LATA Trial: HIV Injections Beat Daily Pills

Analysis based on 6 articles · First reported Sep 20, 2026 · Last updated Sep 21, 2026

Sentiment
15
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The trial results are positive for makers of long-acting injectable HIV treatments, particularly Johnson & Johnson and ViiV Healthcare, as they support wider adoption and potential expanded labeling in low- and middle-income markets. However, near-term revenue impact is limited by access barriers such as pricing, patents, and cold-chain requirements, so the effect on pharmaceutical equities is likely modest and sentiment-driven.

pharmaceuticals healthcare

A clinical trial led by University College London found that long-acting HIV injections given every eight weeks kept the virus suppressed more effectively than daily antiretroviral tablets among adolescents. The LATA (Long-Acting Treatment in Adolescents) trial involved 476 adolescents aged 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe. Participants were randomly assigned either standard daily tablet treatment or injections containing the long-acting HIV medicines cabotegravir and rilpivirine. Findings published in The Lancet showed that only two adolescents, or 1 per cent, receiving the injectable treatment experienced confirmed viral rebound after 96 weeks, compared with 15, or 6 per cent, among those taking daily tablets. Nearly all participants in the injectable group, 94 per cent, said receiving treatment every eight weeks was much easier than taking medicines every day. Researchers, including chief investigator Professor Sarah Pett, called for wider access to the treatment in low- and middle-income settings, noting that nine out of 10 adolescents with HIV live in Africa yet currently cannot access the treatment. The trial was funded by the European Union through EDCTP-2 and Johnson & Johnson Innovative Medicines, which provided injectable rilpivirine, while ViiV Healthcare provided injectable cabotegravir. UCL was the study sponsor. Researchers from Kenya, South Africa, Uganda and Zimbabwe contributed to the trial, with additional involvement from the London School of Hygiene and Tropical Medicine, Radboud University Medical Center and the University of York. The World Health Organization currently recommends long-acting injectables as an alternative option for adults and adolescents who have successfully suppressed HIV and do not have active hepatitis B. Expanding access faces challenges including higher cost, patents, refrigeration requirements for rilpivirine, and the need for trained nursing staff.

35 World Health Organization recommended injectables
30 Sarah Pett called for access
25 Deborah Ford warned of inequalities
25 Mutsa Bwakura-Dangarembizi called for availability
stock
Johnson & Johnson Innovative Medicines funded the trial and provided injectable rilpivirine, potentially benefiting from wider adoption of the regimen.
Importance 65.0 Sentiment 15.0
priv
ViiV Healthcare provided injectable cabotegravir for the trial, and positive results could support expanded use of its product.
Importance 60.0 Sentiment 15.0
per
Professor Sarah Pett was chief investigator of the LATA trial and called for wider availability of injectable treatment for adolescents.
Importance 60.0 Sentiment 5.0
ngo
The WHO currently recommends long-acting injectables as an alternative option, and the trial results may inform future guidance.
Importance 50.0 Sentiment 5.0
alliance
The European Union funded the trial through EDCTP-2, supporting research into HIV treatment access in low-resource settings.
Importance 45.0 Sentiment 5.0
per
Dr Deborah Ford was the study's corresponding author and warned that lack of availability in Africa risks increasing inequalities in HIV care.
Importance 45.0 Sentiment 5.0
per
Dr Mutsa Bwakura-Dangarembizi was the trial physician and principal investigator of the Harare site, calling for action to make injectables available in Africa.
Importance 45.0 Sentiment 5.0
cnt
South Africa hosted trial clinics and contributed researchers; the country stands to benefit from expanded injectable access.
Importance 40.0 Sentiment 5.0
cnt
Kenya hosted trial clinics and contributed researchers; the country stands to benefit from expanded injectable access.
Importance 40.0 Sentiment 5.0
cnt
Uganda hosted trial clinics and contributed researchers; the country stands to benefit from expanded injectable access.
Importance 40.0 Sentiment 5.0
cnt
Zimbabwe hosted trial clinics and contributed researchers; the country stands to benefit from expanded injectable access.
Importance 40.0 Sentiment 5.0
World Health Organization operator ↔ Uganda The World Health Organization operates a country office in Uganda, collaborating with the national government to manage
European Union related ↔ Kenya
European Union related ↔ Uganda
South Africa related ↔ Kenya
South Africa related ↔ Uganda
Kenya related ↔ Uganda
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.